Peptide-based therapeutics are increasingly at the forefront in addressing new challenges due to their high target selectivity and potency with low toxicity. However, peptides can be subject to high enzymatic degradation and poor membrane permeation. These drawbacks can be overcome by peptidomimetics such as peptoids, which have decreased susceptibility to enzymatic degradation and improved membrane permeability resulting in increased bioavailability. Automated solid phase peptide synthesis (SPPS) increases reliability, efficiency, and crude purity for peptides and peptoids.
Read more by downloading the PDF